Mixed Reality Software Device Enables Surgeons to Plan Complex Procedures Using Immersive 3D Holographic Technology

The third-leading cause of death globally is surgeries plus 30 days post operative care. This is more than HIV, malaria and tuberculosis combined. 50% of surgical adverse events happen due to human error. Surgeons across all medical fields experience the same problem because they can’t plan for what they can’t see and have limited support in the operating room. Now, that could change with a pioneering mixed reality software device that enables surgeons to plan complex procedures using the power of immersive 3D holographic technology.

VSI HoloMedicine from apoQlar GmbH (Hamburg, Germany) is a medically certified software platform that leverages the Microsoft HoloLens 2 hardware to transform medical images, clinical workflows and medical education into a 3D mixed reality environment the world has never seen before. VSI HoloMedicine gives surgeons an almost "X-ray vision" perspective in surgical planning processes using 3D holographic technology. Physicians across any medical field can now plan surgeries in 3D and visualize medical data inside or outside of the operating room. Using Microsoft's HoloLens 2, a mixed reality head-mounted display (HMD), surgeons can transform otherwise flat CT, Angio CT, MRI, CBCT, PET, and SPECT sources into interactive 3D holograms. apoQlar has received FDA 510(k) Class II clearance for VSI HoloMedicine and now plans to scale VSI Holomedicine as the foundation of modern surgical care.

"With mixed reality, we are no longer bound to physical objects in a physical world. We can leverage digital objects and services on top of the real world for equal or greater utility and usually at a fraction of the cost. Mixed Reality is a completely new way for people, and in our case surgeons, physicians and technologists, to continue to experience the real world around them but with an entire virtual layer placed on top" said Sirko Pelzl, Co-Founder & CEO of apoQlar.

Related Links:
apoQlar GmbH